Researches and develops pharmaceutical products. Manufactures pharmaceutical products. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Against everything we grade, NONOF lands somewhere in the middle. The grade moves as the numbers move.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.